Publications by authors named "J Vaarwater"

Article Synopsis
  • The study aimed to better classify uveal melanoma (UM) cell lines by examining their genetic and expression profiles, particularly focusing on identifying any underlying genetic causes for their behavior.
  • Researchers analyzed 14 UM cell lines using techniques like next-generation sequencing and SNP arrays to assess protein and mRNA expression, and to identify genetic variants.
  • Results indicated that cell lines Mel285 and Mel290, which do not have typical UM mutations, possess distinct genetic alterations and expression profiles, making them potentially unsuitable for research on therapeutic targets for UM.
View Article and Find Full Text PDF

Purpose: To explore the genetic background of choroidal and ciliary body melanoma among children and young adults, with special focus on BAP1 germline variants in this age group.

Methods: Patients under the age of 25 and with confirmed choroidal or ciliary body melanoma were included in this retrospective, multicenter observational study. Nuclear BAP1 immunopositivity was used to evaluate the presence of functional BAP1 in the tumor.

View Article and Find Full Text PDF

Purpose: Gain of chromosome 8q has been associated with poor prognosis in uveal melanoma (UM), and an increase in the absolute number of 8q-copies correlated with an even shorter survival. Splicing factor 3b subunit 1 ()-mutated () tumors display structural chromosomal anomalies and frequently show a partial gain of chromosome 8qter. A recent subset of UM with early-onset metastases has been identified, prompting the investigation of the relationship between survival, 8q gain, and UM.

View Article and Find Full Text PDF

Uveal melanomas (UM) are detected earlier. Consequently, tumors are smaller, allowing for novel eye-preserving treatments. This reduces tumor tissue available for genomic profiling.

View Article and Find Full Text PDF

Approximately 25% of all uveal melanoma (UM) contain driver mutations in the gene encoding the spliceosome factor , and whilst patients with such mutations generally have an intermediate risk on developing metastatic disease, a third of these patients develop early metastasis within 5 years after diagnosis. We therefore investigated whether clinical and/or genetic variables could be indicative of short progression-free survival (PFS < 60 months) or long PFS (PFS ≥ 60 months) for -mutated () UM patients. We collected 146 UM from our Rotterdam Ocular Melanoma Studygroup (ROMS) database and external published datasets.

View Article and Find Full Text PDF